Description

MMAE-SMCC is a agent-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody agent conjugate.–20°C (Powder, protect from light, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C58H89N7O14S-Citation–References-[1]Tang F, et al. One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates. Org Biomol Chem. 2016 Oct 12;14(40):9501-9518.-CASNumber-2021179-11-1-MolecularWeight-1140.43-Compound Purity-99.56-SMILES-O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@@]([C@@H](C)CC)([H])N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCSC(C3)C(N(CC4CCC(C(ON5C(CCC5=O)=O)=O)CC4)C3=O)=O)=O)=O)=O)=O)OC)=O-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related